India Pharma Outlook Team | Friday, 27 March 2026
Alkem Laboratories has announced the launch of its semaglutide injection in India, introducing a more affordable option for patients managing type 2 diabetes and weight issues.
Marketed under the brand names Semasize, Obesema, and Hepaglide, the therapy is administered once a week via subcutaneous injection, with prices starting at Rs. 450 per week.
The company’s semaglutide injection in India is available in a pre-filled disposable pen containing four doses for a month, priced at Rs. 1,800. For patients needing higher maintenance doses, Alkem is also offering a reusable injection pen. This allows users to replace only the medication cartridge, helping reduce long-term costs and improve adherence to treatment.
Also Read: Consumer Trust in OTC Products: The Science Behind Safety
The launch comes after approval from the Drug Controller General of India (DCGI) for treating type 2 diabetes mellitus and chronic weight management. The approval is based on Phase 3 clinical trials conducted in India. The drug is prescription-only and must be used under medical supervision.
Commenting on the launch, Vikas Gupta, CEO of Alkem, said, "We believe therapeutic advancements must translate into real-world access to create a lasting impact. With the launch of our indigenously-developed semaglutide, we are bringing a high-quality and affordable option to market, empowering healthcare practitioners to offer this therapy to more deserving patients.
"Through our strong distribution network and patient-friendly devices, we aim to make the product accessible to a larger section of the population and contribute to better overall healthcare outcomes."
With this move, Alkem aims to expand access to affordable semaglutide therapy in India, potentially improving care for millions dealing with diabetes and obesity.
.jpg)
.jpg)
